Organon & Co | OGN - Current Liabilities


Organon & Co reported $2.5B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Celltrion KRW 292.71B 9.09B Mar/2026
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 38.28M 7.55M Mar/2026
Divis Laboratories Ltd INR 20.43B 3.15B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Kangmei Pharma CNY 5.38B 433.79M Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Organigram Holdings CAD 88.74M 5.31M Mar/2026
Organon & Co USD 2.5B 110M Mar/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pharma Mar EUR 98.42M 9.2M Jun/2026
Qiagen NV USD 479.11M 33.03M Mar/2026
Sartorius EUR 1.44B 668.7M Jun/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Tilray USD 259.32M 8.32M Sep/2025
Zealand Pharma A/S 404M 260.96M Mar/2026